United Pharmaceutical-Y Biologics develops new ADC anticancer drug < Industry < News < Text of article

United Pharmaceutical Korea (CEO Deok-young Kang) and UNS Bio (CEO Won-ho Kang) announced on the 25th that they signed a memorandum of understanding with Y Biologics for the development of a new Antibody Drug Conjugate (ADC) anticancer drug.

Through this agreement, the three companies plan to conduct joint research on the development of new ADC anticancer drugs and present a new cooperation model for innovative new drug development by combining the specialized expertise of each company.

First, United Pharmaceutical Korea is responsible for developing toxic small molecule drugs optimized for ADCs. Korea United Pharmaceutical, which specializes in the development of improved new drugs and new formulations, plans to develop payloads and produce ADCs with optimized drug effects as it possesses various original technologies and patented formulation technologies.

UNS-Bio, a new anticancer drug research institute jointly established by Korea United Pharmaceutical and Seoul National University Technology Holdings, is responsible for the ADC development and approval process, and Y Biologics, an antibody new drug development platform company, is responsible for developing antibodies that provide targeting to ADCs. .

Through this, the three companies are expected to increase their research capabilities for new drug development and efficiently manage the time and cost of new drug development.

Attending the agreement ceremony on this day were Kang Won-ho, CEO of Korea United Pharmaceutical and UN S-Bio, and Park Young-woo and Jang Woo-ik, representatives of Y Biologics, respectively.

CEO Kang Won-ho said, “We are happy to collaborate with a company with the best technology in the field of antibody drug research and development. By signing this MOU, we will accelerate the development of innovative new anticancer drugs by utilizing each company’s strengths to the fullest.”